A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05917509 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: DTG/3TC
DRUG: Cabotegravir (CAB) LA
DRUG: Rilpivirine (RPV) LA

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]